Mind Medicine (MindMed) Inc MNMD

Alternate Symbol(s): N.MMED.WS | N.MMED | N.MMED.WA | N.MMED.WR

Healthcare

Mind Medicine (MindMed) Inc. is a clinical-stage biopharmaceutical company, which is engaged in developing products to treat brain health disorders. It is developing a pipeline of product candidates, with and without acute perceptual effects, targeting neurotransmitter pathways. This specifically includes pharmaceutically optimized product candidates derived from the psychedelic and empathogen drug classes, including MM-120 and MM-402, the Company's product candidates. MM120, is a proprietary, pharmaceutically optimized form of lysergide D-tartrate that it is developing for the treatment of generalized anxiety disorder (GAD). MM-120 is also being studied in a subperceptual repeat administration dosing regimen for the treatment of attention deficit hyperactivity disorder (ADHD). MM-402, also referred to as R(-)-MDMA, is the Company's form of the R-enantiomer of 3,4-methylenedioxymethampheta (MDMA), which the Company is developing for the treatment of autism spectrum disorder (ASD).

NDAQ:MNMD - Post by User

Mind Medicine (MindMed) Inc

Bullboard Posts

Comment by grumpymonkey007on Oct 03, 2010 9:18am

474 Views

Post# 17522713

RE: RE: RE: RE: Can Haywood Lead us to the Promise

Thanks for the input - what you're saying is that 20MM is going against the hedge and 20MM is going against debt without any commitment to the 10MM mill improvement?

23% share dilution without increased production for:
- a 10M increase in cash flow from the hedge, and
- a 20MM reduction in debt to 20MM total debt

Makes sense I guess - they are attempting to present a better cash flow picture at the expense of EPS. I think there will be some trading opportunities in the future. I will probably take some off the table to lock in the 39% profit on Monday then and wait until they commit to mill improvements.

Bullboard Posts

Defence Therapeutics touts anticancer treatment and immune booster